Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.
Eli Lilly Taps High-Grade Market to Fund Cancer Drug Purchase
Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...
Diabetes Drug Market Size to Surpass USD 145 Billion by 2032 at a CAGR of 6.9%, Fueled by Rising Global Diabetes Prevalence – SNS Insider
Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...
Eli Lilly enters global license agreement with OliX for OLX75016
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...
PharmiWeb13h
Active Pharmaceutical Ingredient (API) Market Size, Share and Growth Report 2025-2034
Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...
Boris Becker's ex-wife Lilly wins German version of I'm A Celebrity... Get Me Out Of Here! as model wins over hearts of the nation after bitter divorce with tennis star
Former Wimbledon tennis star Boris Becker and his ex-wife Lilly were married for nine years and welcomed son Amadeus, 14, ...
Korea Joongang Daily on MSN16h
Olix, Eli Lilly to develop liver disease drug under $630 million deal
Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...